Neoadjuvant Versus Adjuvant Chemotherapy Survival in Triple-Negative Breast Cancer
Triple-negative breast cancer (TNBC) accounts for 12% to 20% of all forms of BC. As it is generally associated with a poorer outcome compared with non-TNBC, various treatment modalities have been explored, including neoadjuvant (chemotherapy delivered before the main treatment) and adjuvant chemotherapy (chemotherapy delivered after the primary treatment). Which of these treatment options better improves outcomes? Read more.

Breast Cancer Treatment and COVID-19: What Do We Know?
Medical conditions such as diabetes and hypertension have been associated with an increased risk of severe illness secondary to COVID-19, but what role does breast cancer have in developing serious coronavirus infection? Two clinical studies, one from New York City and one from Paris, France, explored this issue. Read more. 

New Treatment-Induced Hot Flash Management Guidelines
Hot flashes or vasomotor symptoms occur in up to 80% of women and men receiving treatment for reproductive-organ malignancies. These symptoms, which may be debilitating, can interfere with sleep quality, energy, mood, and sexual function. The Oncologic Nursing Society recently published guidelines that review the assessment of hot flashes as well as nonpharmacological and pharmacological interventions. Read more.